Testing beyond 70 and mpMRI before biopsy are also among the key changes in Australia’s first major overhaul of prostate cancer early detection guidance in a decade.
Australia’s prostate cancer detection guidelines have had their first major overhaul in a decade, with individual risk, shared decision-making, and MRI taking a more prominent role in the diagnostic pathway.
The NHMRC-approved 2026 Guidelines for the Early Detection of Prostate Cancer in Australia, developed by the Prostate Cancer Foundation of Australia, replace the 2016 guidance and shift the emphasis towards identifying clinically significant disease while limiting unnecessary biopsy and treatment.
Professor Jeff Dunn AO, chair of the Guideline Steering Committee, said the new guidelines represented a watershed moment in Australia’s approach to prostate cancer.
“These guidelines represent the culmination of years of scientific work, national collaboration, and rigorous evaluation of the evidence,” he said.
“Much has changed over the past decade. The evidence has matured, diagnostic technologies have advanced, and clinical practice has evolved substantially.
“For the first time, Australia now has a contemporary national framework that better balances the benefits of detecting aggressive prostate cancer early with the need to minimise unnecessary harms.
“Our ambition is simple: to ensure every Australian man has access to the very best evidence available, giving him the greatest possible opportunity to detect clinically significant prostate cancer early, receive timely treatment where required, and ultimately reduce his risk of dying from this disease.”
The guidelines defined clinically significant prostate cancer as ISUP grade group 2 or higher and explicitly frame early detection as an individualised, risk-adapted, and harm-minimisation strategy incorporating PSA, mpMRI, biopsy technique, and subsequent management, including active surveillance.
One of the most consequential changes was the formalisation of separate PSA thresholds according to age and baseline risk.
For men aged 50-69 at usual risk who elected testing following shared decision-making, two-yearly PSA testing was recommended.
A PSA of at least 3.0µg/L should be repeated within one to three months and, if confirmed, trigger referral for further investigation.
But the threshold has fallen substantially for men classified as higher risk.
Two-yearly PSA testing was proposed from age 45 years for this group. In men aged 45-49, a PSA of at least 1.0µg/L should be repeated within one to three months, with referral and further investigation considered if confirmed. For higher-risk men aged 50-69, the equivalent threshold is 2.0µg/L.
Higher risk was defined as at least twice the general Australian male population’s risk of clinically significant prostate cancer or prostate cancer mortality.
The category includes men with a brother diagnosed with prostate cancer, a father diagnosed before age 65 years, or two or more second-degree relatives who died from prostate cancer, as well as men of sub-Saharan African ancestry and men with a BRCA2 pathogenic variant.
The guidelines also flagged hereditary breast and ovarian cancer syndromes and Lynch syndrome as being associated with increased risk of clinically significant disease.
The family history criteria extended further. Men whose father was diagnosed with prostate cancer at any age were conditionally considered at higher risk of prostate cancer mortality, while having two or more second-degree relatives diagnosed with the disease was included through a consensus recommendation.
The new guidance also moved away from a rigid upper age boundary for PSA testing.
Men aged 70 years and older may be offered two-yearly PSA testing after clinical assessment and discussion of benefits and harms. Testing was not recommended where life expectancy was seven years or less, while comorbidities and patient preferences should inform the decision.
For this group, a PSA threshold of 5.5µg/L triggers repeat testing within one to three months and consideration of specialist referral if confirmed. Testing should cease where limited life expectancy or comorbidity meant prostate cancer treatment was unlikely to improve quality or length of life.
Men over 70 years with PSA below 5.5µg/L may discontinue testing altogether, although continued testing remained an option after individualised assessment.
Once a patient reached specialist care, mpMRI took a central position in determining who proceeds to biopsy.
The guidelines recommend mpMRI as the next diagnostic investigation for men requiring further assessment on the basis of PSA.
Biopsy was suggested for men with PI-RADS 4-5 lesions and for those with equivocal PI-RADS 3 imaging where PSA density is at least 0.15µg/L/mL.
Conversely, men with PI-RADS 3 lesions and PSA density below 0.15µg/L/mL may not require biopsy, subject to clinical assessment.
The pathway reinforced the move towards MRI-informed biopsy selection rather than proceeding directly from an elevated PSA to tissue diagnosis.
Digital rectal examination was also more clearly separated between primary and specialist care. Routine DRE as an adjunct to PSA testing and risk assessment in primary care was conditionally recommended against, but the examination remained part of specialist assessment before consideration of biopsy.
The guidelines retained a strong emphasis on avoiding detection and treatment cascades unlikely to benefit patients. Shared decision-making was expected before PSA testing, with discussions encompassing potential benefits, harms and downstream consequences.
The recommendations were approved by the NHMRC in May. Most remain approved until May 2031, while the primary-care PSA testing recommendations have a shorter two-year approval period, expiring in May 2028, reflecting the potential for emerging evidence to alter the screening pathway.
Related
Adjunct Professor Peter Heathcote, chair of the Guideline Expert Advisory Panel, said advances in diagnosis had fundamentally changed the way clinicians investigate prostate cancer.
“Modern prostate cancer diagnosis is no longer based on a PSA blood test alone,” he said.
“Today’s diagnostic pathway incorporates individual risk assessment, shared decision-making, multiparametric MRI before biopsy, targeted biopsy techniques, and active surveillance for men with low-risk disease.
“These advances allow clinicians to identify clinically significant cancers more accurately while reducing unnecessary biopsies, significantly reducing risks of overtreatment, and ensuring we protect men’s quality of life while managing individual risks.”
The federal government has backed implementation with $320,000 for the RACGP to develop GP education and awareness activities, following $770,000 provided to support development of the guidelines.
For urologists and oncologists, the practical effect is likely to be a changing referral population, meaning earlier investigation of men with defined high-risk features, higher thresholds and greater clinical discretion among older men, and more systematic use of mpMRI and PSA density to determine who needs biopsy.
Prostate Cancer Foundation of Australia chief executive Anne Savage said publication of the guidelines marked the beginning of Australia’s next challenge.
“Developing world-class Guidelines is only half the task. Now we must ensure they are implemented,” she said.
“Evidence only saves lives when it reaches the men who need it. Australian men need to understand their individual risk, know when to have the conversation with their GP, and be supported by clinicians with access to the latest evidence.
“These Guidelines provide Australia with an extraordinary opportunity to reduce deaths from our most commonly diagnosed cancer. Realising that opportunity will require coordinated implementation, clinician education, consumer awareness, and ongoing investment in evidence-based care.
“If we get implementation right, future generations of Australian men will look back on these Guidelines as the moment Australia fundamentally changed its approach to prostate cancer early detection.”
Read the full guidelines here.
